{{unreferenced|date=March 2015}}

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408580400
| IUPAC_name = 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
| image = Loviride.svg
| width = 175

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 147362-57-0
| ATC_prefix = None
| ATC_suffix =
| ATC_supplemental =
| PubChem = 3963
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3826
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 3S1R1LZ09H
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04786
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 37624

<!--Chemical data-->
| C=17 | H=16 | Cl=2 | N=2 | O=2 
| molecular_weight = 351.227 g/mol
| smiles = Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CJPLEFFCVDQQFZ-UHFFFAOYSA-N
| synonyms = R089439
}}

'''Loviride''' (also called '''loveride'''{{Citation needed|date=February 2010}}) was an antiviral drug manufactured by [[Janssen Pharmaceutica|Janssen]] (now part of [[Janssen-Cilag]]) that is active against [[HIV]].  Loviride is a [[Reverse-transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)]] that entered [[Phases of clinical research#Phase_III|phase III]] clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing [[reverse transcriptase]] mutations such as K103N which result in cross-class resistance the NNRTIs [[efavirenz]] and [[nevirapine]].

==Synthesis==
[[File:Loviride synthesis.png|thumb|center|600px|Loviride synthesis: [[Janssen Pharmaceutica]] {{US patent|5407961}} (1995).]]

==External links==
* [http://www.aidsmap.com/cms1032278.asp aidsmap]

{{HIVpharm}}

[[Category:Abandoned drugs]]
[[Category:Acetamides]]
[[Category:Anilines]]
[[Category:Aromatic ketones]]
[[Category:Chloroarenes]]

{{antimicrobial-stub}}